|
1
|
Banerjee A, Pathak S, Subramanium VD, G D,
Murugesan R and Verma RS: Strategies for targeted drug delivery in
treatment of colon cancer: Current trends and future perspectives.
Drug Discov Today. 22:1224–1232. 2017. View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar
|
|
3
|
Iqbal A and George TJ: Randomized clinical
trials in colon and rectal cancer. Surg Oncol Clin N Am.
26:689–704. 2017. View Article : Google Scholar
|
|
4
|
Avila-Carrasco L, Majano P, Sánchez-Toméro
JA, Selgas R, López-Cabrera M, Aguilera A and González Mateo G:
Natural plants compounds as modulators of epithelial-to-mesenchymal
transition. Front Pharmacol. 10:7152019. View Article : Google Scholar
|
|
5
|
Wang Y, Chen J, Wang L, Huang Y, Leng Y
and Wang G: Fangchinoline induces G0/G1 arrest by modulating the
expression of CDKN1A and CCND2 in K562 human chronic myelogenous
leukemia cells. Exp Ther Med. 5:1105–1112. 2013. View Article : Google Scholar
|
|
6
|
Feng T, Ding D and Li DD: Fangchinoline
targets PI3K and suppresses PI3K/AKT signaling pathway in SGC7901
cells. Int J Oncol. 46:2355–2363. 2015. View Article : Google Scholar
|
|
7
|
Wu WK, Wang XJ, Cheng AS, Luo MX, Ng SS,
To KF, Chan FK, Cho CH, Sung JJ and Yu J: Dysregulation and
crosstalk of cellular signaling pathways in colon carcinogenesis.
Crit Rev Oncol Hematol. 86:251–277. 2013. View Article : Google Scholar
|
|
8
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar
|
|
9
|
Barr S, Thomson S, Buck E, Russo S, Petti
F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW,
Miglarese M, et al: Bypassing cellular EGF receptor dependence
through epithelial-to-mesenchymal-like transitions. Clin Exp
Metastasis. 25:685–693. 2008. View Article : Google Scholar
|
|
10
|
Kim N, Cho D, Kim H, Kim S, Cha YJ,
Greulich H, Bass A, Cho HS and Cho J: Colorectal
adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to
EGFR-targeted monoclonal antibodies, cetuximab and panitumumab. Int
J Cancer. 146:2194–2200. 2020. View Article : Google Scholar
|
|
11
|
Padfield E, Ellis HP and Kurian KM:
Current therapeutic advances targeting EGFR and EGFRvIII in
glioblastoma. Front Oncol. 5:52015. View Article : Google Scholar
|
|
12
|
Li Z, Chen Y, An T, Liu P, Zhu J, Yang H,
Zhang W, Dong T, Jiang J, Zhang Y, et al: Nuciferine inhibits the
progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug
signaling pathway. J Exp Clin Cancer Res. 38:1392019. View Article : Google Scholar
|
|
13
|
Vermeulen K, Berneman ZN and Van
Bockstaele DR: Cell cycle and apoptosis. Cell Prolif. 36:165–175.
2003. View Article : Google Scholar
|
|
14
|
Russo A, Terrasi M, Agnese V, Santini D
and Bazan V: Apoptosis: A relevant tool for anticancer therapy. Ann
Oncol. 17 (Suppl 7):vii115–vii123. 2006. View Article : Google Scholar
|
|
15
|
Qian L, Liu Y, Xu Y, Ji W, Wu Q, Liu Y,
Gao Q and Su C: Matrine derivative WM130 inhibits hepatocellular
carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling
pathways. Cancer Lett. 368:126–134. 2015. View Article : Google Scholar
|
|
16
|
Sak K: Cytotoxicity of dietary flavonoids
on different human cancer types. Pharmacogn Rev. 8:122–146. 2014.
View Article : Google Scholar
|
|
17
|
Boldbaatar A, Lee S, Han S, Jeong AL, Ka
HI, Buyanravjikh S, Lee JH, Lim JS, Lee MS and Yang Y: Eupatolide
inhibits the TGF-β1-induced migration of breast cancer cells via
downregulation of SMAD3 phosphorylation and transcriptional
repression of ALK5. Oncol Lett. 14:6031–6039. 2017.
|
|
18
|
Vuddanda PR, Chakraborty S and Singh S:
Berberine: A potential phytochemical with multispectrum therapeutic
activities. Expert Opin Invest Drugs. 9:1297–1307. 2010. View Article : Google Scholar
|
|
19
|
Hang Y, Qin X, Ren T and Cao J: Baicalin
reduces blood lipids and inflammation in patients with coronary
artery disease and rheumatoid arthritis: A randomized,
double-blind, placebo-controlled trial. Lipids Health Dis.
17:1462018. View Article : Google Scholar
|
|
20
|
Ferk F, Kundi M, Brath H, Szekeres T,
Al-Serori H, Mišík M, Saiko P, Marculescu R, Wagner KH and
Knasmueller S: Gallic acid improves health-associated biochemical
parameters and prevents oxidative damage of DNA in type 2 diabetes
patients: Results of a placebo-controlled pilot study. Mol Nutr
Food Res. 62:Jan 18–2018.(Epub ahead of print). doi:
10.1002/mnfr.201700482. View Article : Google Scholar
|
|
21
|
McCubrey JA, Lertpiriyapong K, Steelman
LS, Abrams SL, Yang LV, Murata RM, Rosalen PL, Scalisi A, Neri LM,
Cocco L, et al: Effects of resveratrol, curcumin, berberine and
other nutraceuticals on aging, cancer development, cancer stem
cells and microRNAs. Aging (Albany NY). 9:1477–1536. 2017.
View Article : Google Scholar
|
|
22
|
Kang M, Kim S and Ko J: Roles of CD133 in
microvesicle formation and oncoprotein trafficking in colon cancer.
FASEB J. 33:4248–4260. 2019. View Article : Google Scholar
|
|
23
|
Zhang SS, Han ZP, Jing YY, Tao SF, Li TJ,
Wang H, Wang Y, Li R, Yang Y, Zhao X, et al: CD133(+)CXCR4(+) colon
cancer cells exhibit metastatic potential and predict poor
prognosis of patients. BMC Med. 10:852012. View Article : Google Scholar
|
|
24
|
Lu P, Weaver VM and Werb Z: The
extracellular matrix: A dynamic niche in cancer progression. J Cell
Biol. 196:395–406. 2012. View Article : Google Scholar
|
|
25
|
Zucker S and Vacirca J: Role of matrix
metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis
Rev. 23:101–117. 2004. View Article : Google Scholar
|
|
26
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar
|
|
27
|
Han YT, Chen XH, Gao H, Ye JL and Wang CB:
Physcion inhibits the metastatic potential of human colorectal
cancer SW620 cells in vitro by suppressing the transcription factor
SOX2. Acta Pharmacol Sin. 37:264–275. 2016. View Article : Google Scholar
|
|
28
|
Beyes S, Andrieux G, Schrempp M, Aicher D,
Wenzel J, Antón-García P, Boerries M and Hecht A: Genome-wide
mapping of DNA-binding sites identifies stemness-related genes as
directly repressed targets of SNAIL1 in colorectal cancer cells.
Oncogene. 38:6647–6661. 2019. View Article : Google Scholar
|
|
29
|
Chen T, You Y, Jiang H and Wang ZZ:
Epithelial-mesenchymal transition (EMT): A biological process in
the development, stem cell differentiation, and tumorigenesis. J
Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar
|
|
30
|
Zhao GX, Xu YY, Weng SQ, Zhang S, Chen Y,
Shen XZ, Dong L and Chen S: CAPS1 promotes colorectal cancer
metastasis via Snail mediated epithelial mesenchymal
transformation. Oncogene. 38:4574–4589. 2019. View Article : Google Scholar
|
|
31
|
Kahlert C, Lahes S, Radhakrishnan P, Dutta
S, Mogler C, Herpel E, Brand K, Steinert G, Schneider M,
Mollenhauer M, et al: Overexpression of ZEB2 at the invasion front
of colorectal cancer is an independent prognostic marker and
regulates tumor invasion in vitro. Clin Cancer Res. 17:7654–7663.
2011. View Article : Google Scholar
|
|
32
|
Li MZ, Wang JJ, Yang SB, Li WF, Xiao LB,
He YL and Song XM: ZEB2 promotes tumor metastasis and correlates
with poor prognosis of human colorectal cancer. Am J Transl Res.
9:2838–2851. 2017.
|
|
33
|
Wu K, Wei P, Liu M, Liang X and Su M: To
reveal pharmacological targets and molecular mechanisms of curcumol
against interstitial cystitis. J Adv Res. 20:43–50. 2019.
View Article : Google Scholar
|
|
34
|
Cheng F, Kovacs IA and Barabasi AL:
Network-based prediction of drug combinations. Nat Commun.
10:11972019. View Article : Google Scholar
|
|
35
|
Wang Y, Wang S and Huang M: Structure and
enzymatic activities of human serum albumin. Curr Pharm Des.
21:1831–1836. 2015. View Article : Google Scholar
|
|
36
|
Bauer J and Capra S: Comparison of a
malnutrition screening tool with subjective global assessment in
hospitalised patients with cancer-sensitivity and specificity. Asia
Pac J Clin Nutr. 12:257–260. 2003.
|
|
37
|
McMillan DC, Watson WS, O'Gorman P,
Preston T, Scott HR and McArdle CS: Albumin concentrations are
primarily determined by the body cell mass and the systemic
inflammatory response in cancer patients with weight loss. Nutr
Cancer. 39:210–213. 2001. View Article : Google Scholar
|
|
38
|
Yamamoto M, Saito H, Uejima C, Tanio A,
Tada Y, Matsunaga T, Sakamoto T, Honjo S, Ashida K and Fujiwara Y:
Combination of serum albumin and cholinesterase levels as
prognostic indicator in patients Ith colorectal cancer. Anticancer
Res. 39:1085–1090. 2019. View Article : Google Scholar
|
|
39
|
Pal I and Mandal M: PI3K and Akt as
molecular targets for cancer therapy: Current clinical outcomes.
Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar
|
|
40
|
Lossi L, Castagna C and Merighi A:
Caspase-3 mediated cell death in the normal development of the
mammalian cerebellum. Int J Mol Sci. 19:39992018. View Article : Google Scholar
|
|
41
|
Chen H, Yang X, Feng Z, Tang R, Ren F, Wei
K and Chen G: Prognostic value of caspase-3 expression in cancers
of digestive tract: A meta-analysis and systematic review. Int J
Clin Exp Med. 8:10225–10234. 2015.
|
|
42
|
Lieu C and Kopetz S: The SRC family of
protein tyrosine kinases: A new and promising target for colorectal
cancer therapy. Clin Colorectal Cancer. 9:89–94. 2010. View Article : Google Scholar
|
|
43
|
Parkin A, Man J, Timpson P and Pajic M:
Targeting the complexity of Src signalling in the tumour
microenvironment of pancreatic cancer: From mechanism to therapy.
FEBS J. 286:3510–3539. 2019. View Article : Google Scholar
|
|
44
|
Kopetz S: Targeting SRC and epidermal
growth factor receptor in colorectal cancer: Rationale and progress
into the clinic. Gastrointest Cancer Res. 1 (Suppl 2):S37–S41.
2007.
|
|
45
|
Maa MC, Leu TH, McCarley DJ, Schatzman RC
and Parsons SJ: Potentiation of epidermal growth factor
receptor-mediated oncogenesis by c-Src: Implications for the
etiology of multiple human cancers. Proc Natl Acad Sci USA.
92:6981–6985. 1995. View Article : Google Scholar
|
|
46
|
Poole EM, Curtin K, Hsu L, Kulmacz RJ,
Duggan DJ, Makar KW, Xiao L, Carlson CS, Slattery ML, Caan BJ, et
al: Genetic variability in EGFR, Src and HER2 and risk of
colorectal adenoma and cancer. Int J Mol Epidemiol Genet.
2:300–315. 2011.
|
|
47
|
Chen J, Elfiky A, Han M, Chen C and Saif
MW: The role of Src in colon cancer and its therapeutic
implications. Clin Colorectal Cancer. 13:5–13. 2014. View Article : Google Scholar
|
|
48
|
Lin L, Cheng K, He Z, Lin Q, Huang Y, Chen
C, Xie Z, Chen L and Liang Z: A polysaccharide from hedyotis
diffusa interrupts metastatic potential of lung adenocarcinoma A549
cells by inhibiting EMT via EGFR/Akt/ERK signaling pathways. Int J
Biol Macromol. 129:706–714. 2019. View Article : Google Scholar
|
|
49
|
Geethadevi A, Parashar D, Bishop E,
Pradeep S and Chaluvally-Raghavan P: ERBB signaling in CTCs of
ovarian cancer and glioblastoma. Genes Cancer. 8:746–751. 2017.
View Article : Google Scholar
|
|
50
|
Sigismund S, Avanzato D and Lanzetti L:
Emerging functions of the EGFR in cancer. Mol Oncol. 12:3–20. 2018.
View Article : Google Scholar
|
|
51
|
Zhang L, Tao X, Fu Q, Ge C, Li R, Li Z,
Zhu Y, Tian H, Li Q, Liu M, et al: Curcumin inhibits cell
proliferation and migration in NSCLC through a synergistic effect
on the TLR4/MyD88 and EGFR pathways. Oncol Rep. 42:1843–1855.
2019.
|
|
52
|
Li C, Cai G, Song D, Gao R, Teng P, Zhou
L, Ji Q, Sui H, Cai J, Li Q and Wang Y: Development of
EGFR-targeted evodiamine nanoparticles for the treatment of
colorectal cancer. Biomater Sci. 7:3627–3639. 2019. View Article : Google Scholar
|
|
53
|
Wang N, Pan W, Zhu M, Zhang M, Hao X,
Liang G and Feng Y: Fangchinoline induces autophagic cell death via
p53/sestrin2/AMPK signalling in human hepatocellular carcinoma
cells. Br J Pharmacol. 164:731–742. 2011. View Article : Google Scholar
|
|
54
|
Suman S, Kurisetty V, Das TP, Vadodkar A,
Ramos G, Lakshmanaswamy R and Damodaran C: Activation of AKT
signaling promotes epithelial-mesenchymal transition and tumor
growth in colorectal cancer cells. Mol Carcinog. 53 (Suppl
1):E151–E160. 2014. View Article : Google Scholar
|
|
55
|
Shi J, Guo B, Hui Q, Chang P and Tao K:
Fangchinoline suppresses growth and metastasis of melanoma cells by
inhibiting the phosphorylation of FAK. Oncol Rep. 38:63–70. 2017.
View Article : Google Scholar
|
|
56
|
Xia J, Chen J, Zhang Z, Song P, Tang W and
Kokudo N: A map describing the association between effective
components of traditional Chinese medicine and signaling pathways
in cancer cells in vitro and in vivo. Drug Discov Ther. 8:139–153.
2014. View Article : Google Scholar
|
|
57
|
Bahrami B, Hojjat-Farsang M, Mohammadi H,
Anvari E, Ghalamfarsa G, Yousefi M and Jadidi-Niaragh F:
Nanoparticles and targeted drug delivery in cancer therapy. Immunol
Lett. 190:64–83. 2017. View Article : Google Scholar
|
